ECONOMICS OF VACCINE PRODUCTION COSTING

Benoit Hayman
DCVMN International
Introduction

Topics covered in this presentation include:
1) Vaccine market structure
2) Outline of cost structures
3) Strategies to reduce cost drivers
4) Economic shocks
5) Economic decision making

*Much of the content of this presentation is based on the following sources:
Vaccine Market Structure

Price taker markets (competitive, many suppliers)

- Domestic markets
- Export (procurement agencies)

Monopoly markets (price setting, few suppliers)

Novel products

https://economicsconcepts.com/long_run_equilibrium_of_the_price_taker_firm.htm

https://en.wikipedia.org/wiki/Monopolistic_competition
Price-taker vs Monopoly markets

<table>
<thead>
<tr>
<th>Lower R&amp;D cost with tech transfer</th>
<th>Do not influence price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stable prices</td>
<td>Homogenous product</td>
</tr>
<tr>
<td></td>
<td>Low barriers to entry</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>High prices</th>
<th>Market share</th>
</tr>
</thead>
<tbody>
<tr>
<td>Royalties</td>
<td>High R&amp;D costs and risk</td>
</tr>
<tr>
<td></td>
<td>International stakeholders want to minimize supply risk</td>
</tr>
</tbody>
</table>

Intravacc transferring Hib conjugate vaccine technology to DCVM producers.

**Partnership for a dengue vaccine**

A Butantan vaccine in final trials leads to a US$100 million agreement with a US pharma company.

https://revistapesquisa.fapesp.br/en/2019/06/26/partnership-for-a-dengue-vaccine/
Cost structures

**Fixed costs**
Product development and facilities and equipment

**Variable costs**
Consumables

**Semi-variable**
Direct labor

**Mixed**
Overhead, Licensing/Regulation and commercialization
Fixed Costs

Most significant cost facing vaccine manufacturers and cause high-entry barriers into market.

Fixed costs require large initial investment but average fixed costs will decline over time with increasing volume.
Fixed Costs

Long product-life cycle and economies of scale are crucial in achieving returns in investment on the fixed costs of vaccine production.

Economies of scale- cost advantages that manufacturers gain from increasing output. In other words, economies of scale will cause decreases in total costs per dose as production volume increases.

https://www.economicsonline.co.uk/Business_economics/Costs.html
Vaccine product development a complex multistep process requiring significant time and financial investment:

- **Exploratory & Pre-clinical**
- **Clinical Trial (Authorization Application)**
- **Post-Licensure monitoring**
- **Phase I-Phase III Vaccine trials**
- **Approval & Licensure**
- **Licensure amendments**

Entire process takes 15 years or more and estimated to cost between 200 and 500 million dollars
Ways to reduce production costs of product development

- Copy originator process post patent expiration
- Perform tech transfer with established product
- Leverage correlates of protection to avoid large efficacy studies
- Purchase antigens and execute form/fill as a means of gaining experience prior to full manufacturing end-to-end.
Risk/Reward tradeoffs in Product development

Development costs vary greatly between vaccine types: Phase I development costs can vary from 2 million USD for translational products to 60 million USD for novel vaccines.

Benefits of R&D in novel vaccine – first to market (monopoly prices), royalties from transfers, BUT high costs of R&D also risks in development failures i.e. efficacy to low.

Manufacturers may choose to obtain technology from MNCs or biotechs to reduce the cost and time inherent to R&D. Low-risk strategy – prices subject to the market, lower revenue.
Facilities and equipment

Capital costs that depreciate over time

Ongoing costs of upkeep
Vaccine manufacturing facilities

Identify optimal capacity and forecast specific market need

Careful assessment of market opportunities required to determine optimal capacity and utilization.

Outcomes

- Underutilized facilities result in additional fixed cost burden increasing the per-unit dose cost
- Capacity not large enough to meet market need can lead to greater opportunity costs
Ways to reduce production costs of facilities and equipment

Plan for high facility utilization (make the most of existing resources):
- Force fit new processes into established platforms
- Increase utilization of existing facilities
- Use multi-dose vials

For example:

- Share filling lines across multiple vaccines when applicable
- Shift production volumes to multi-dose vials to reduce filling costs
Ways to reduce production costs of facilities and equipment

Smaller impact strategies to reduce COGS:

• Use single-use disposable systems to reduce capital cost
• Minimize classified production space with closed systems and Restricted Access Barrier Systems (RABs)
• Leverage blow-fill-seal (BFS) filling technology to shrink clean room footprint and reduce final product component costs, and reduce labor
• Utilize Contract Manufacturing Organizations (CMO) for low volume products or until demand supports facility construction e.g. Seasonal influenza vaccines often produced at a CMO.

For example a management decision to reduce capital cost in (1) would increase operating consumable costs.
Long-term fixed cost reduction

- Long product life
- Scale
- Substitutable technology/operating platforms
- High production volume
Production capacity

Marginal rate of transformation (MRT):

How much of one product do you have to give up to produce one more unit of another product.

Function of technology, and capital and labor inputs – substitutability within these parameters normalizes MRT to one.

\[ f(L, K) = Y = AL^\alpha K^\beta, \]

https://policonomics.com/lp-welfare-economics1-production-possibility-frontier/
### Further Production Economics Costs

**Consumables** – Materials used as inputs in production, including materials

<table>
<thead>
<tr>
<th>Category</th>
<th>Items</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bulk consumables</td>
<td>• Biological agents</td>
</tr>
<tr>
<td>Fill/Finish consumables</td>
<td>• Vials</td>
</tr>
<tr>
<td></td>
<td>• Seals</td>
</tr>
<tr>
<td>Packaging</td>
<td>• Labels</td>
</tr>
<tr>
<td></td>
<td>• Cartons</td>
</tr>
<tr>
<td>QC consumables</td>
<td>• Testing kits</td>
</tr>
<tr>
<td>Shipping</td>
<td>• Freight costs</td>
</tr>
<tr>
<td></td>
<td>• Import tax</td>
</tr>
</tbody>
</table>
Further Production Economics Costs

**Consumables** are the key variable cost in vaccine manufacturing – they increase (decrease) directly with output.

- **Specialized raw materials**
  - Supply shortages and competitiveness
    - Increased prices
    - Shortages disrupt production
      - Minimize supply risk with multiple contracts
        - Higher prices
Further Production Economics Costs

**Direct labor** - fully loaded costs that include all employee costs directly attributable to a specific vaccine e.g. wages, benefits.

- Costs vary by product and manufacturer based on market labor rates, manufacturing labor intensity, worker skill-level required, and complexity of manufacturing processes.

Labor costs differences between developed and developing countries is shrinking?

- Requirements of cGMP practices are increasing
- More developing countries hire consultants and import skilled labor

---

**Increase automation and single-use production technologies**

- Must be balanced with potential increase in equipment or consumable costs
- E.g. Single-use, or disposable bioreactors reduce cleaning and sterilization requirements

**Standardize and streamline processes across as many steps and vaccines as possible**

- E.g. PCV assays are streamlined across multiple serotypes
**Further Production Economics Costs**

**Overhead** – Indirect costs that are necessary for the manufacturer to function, but are not directly attributable to a specific product e.g. management, quality systems, IT systems.

- **High if company has few products**
- **Low if overhead can be allocated across multiple products**

- **Invest in quality systems that can streamline quality practices and reduce costs over long term**
- **Ensure management team has broad expertise to be leveraged across a portfolio of vaccines**
Further Production Economics Costs

Licensing, regulatory and commercialization

- Expenses paid for the right to use product-related IP
- Expenses to comply with regulatory requirements to produce either for domestic markets or exports
- Costs of WHO PQ Process
- Sales and marketing costs
Further Production Economics Costs

Costs minimization strategies:

- Request royalty reductions or waivers for vaccine sold in low income countries (LICs)
  - Royalty for HPV antigens waived for volumes sold in Gavi markets
- Produce reagents in-house or seek viable alternatives rather than license
- Differentiate originator production processes sufficiently to be considered a novel process
- Accelerate approval by seeking NRA or WHO priority review for vaccines for neglected diseases or emergency use
Allocation of Costs

To isolate the costs of resources used in the manufacturing of a specific vaccine, where resources may be used to manufacture and commercialize multiple products.

To isolate the costs of production and introduction for the vaccine specific to a particular geography when the product is sold in multiple markets.

To isolate production costs of a specific vaccine between production steps.

Manufacturers generally allocate costs to different products and market based on *relative revenues or volumes*.

Use of accurate, simple and equitable cost allocations are critical in strategic decision-making and assessments.
Example – technology for cost-effective vaccine manufacturing

Applying process intensification and continuous bioprocessing principles:
- Chaining equipment to semi- or fully continuous format to automate the process
- Reduces equipment, cleanrooms and overall facility cost
- Rapid deployment
- Reduces time and cost to market (demand flexibility)

NevoLine polio vaccine production platform
- 50 million doses at <$0.30
- Approx. 7-fold reduction in CAPEX
Economic shocks

**Systematic vs non-systematic risk**

- Supply and demand shocks
- Changes in industry regulation
- Economic volatility
- Prevalence of emerging disease

- Maintaining pharmacovigilance and bio-safety practices
- Fluctuations in local prices
- Poor QC/QA
- Production failures
Economic fluctuations

Inflation Rates
- Can increase costs of inputs, increasing production costs.

Foreign Exchange rates
- From the time raw materials are purchased to the time the final product (vaccine) is sold exchange rates can fluctuate greatly.
- Exchange rate variability influences costs and revenues of importing and exporting. Simple model: appreciated domestic currency makes importing raw materials more affordable while exports may be less price competitive
- Hedging against currency fluctuations has proven successfully and is an method adopted by many manufacturers.

In any case – forecasts of future inflation and exchange rates should be incorporated in business and product level decisions
→ Using multi-year averages effectively smooth the effect of business cycles.
Decisions based on production economics

Economics, in its simplest form is the science of decision-making:

- Maximizing utility subject to constraints
- Optimizing short and long term effects
- Aligning decision with values
- Accounting for macroeconomic variables

Two key methods in making economic evaluations are **Cost-Benefit Analysis (CBA)** and **Cost-Effectiveness Analysis (CEA and also iCEA)**.
Cost-Benefit Analysis

Decision rule: choosing projects based on positive net present value (NPV) – in monetary terms is the present values of benefits is greater the present value of cost the project should go ahead.

\[
\text{NPV of a project} = CF_0 + \frac{CF_1}{(1+r)^1} + \frac{CF_2}{(1+r)^2} + \frac{CF_3}{(1+r)^3} + \ldots + \frac{CF_n}{(1+r)^n}
\]

Accounts for time value of money and risk.

If NPV is positive should you undertake the project?
Steps in Cost-Effectiveness Evaluation

Before conducting CEA, there are four preliminary considerations to be identified:

- **Baseline**: To determine the baseline to which the alternative program is compared. May include other alternatives i.e. different production platforms.

- **Outcome**: Clearly define outcomes based on objective (maximizing profit, reaching target markets, achieving mandate). Must be discussed with stakeholders, funders, etc.

- **Perspectives**: Viewpoint of the analysis, which costs will be included and attributed to the outcomes. Societal, funder, company perspectives.

- **Time frame**: Analytic horizon in which outcomes and costs are collected must be ascertained.

Haslinda et al, 2007
Cost-Effectiveness Analysis

Decision rule: choose the project with the lowest costs per outcome variable (in health care this is QALYs).
Cost-Effectiveness Analysis

CEA will tell us how efficiently the costs can produce an additional unit of effect.

\[ CEA = \frac{\text{cost}}{\text{units of effectiveness}} \]

**What is the shortcoming?**

Economic analysis is concerned with costs and outcomes of all alternatives (opportunity costs).

We want to know the cost-effective relative to other alternatives, or a threshold (current state)

\[ ICEA = \frac{\text{costs}(B) - \text{costs}(A)}{\text{effect}(B) - \text{effect}(A)} \]
Multi-Criteria Decision-Making

Prioritizing, or ranking, or choosing from amongst competing alternatives or individuals, based on considering multiple criteria (or objectives)

1) Alternatives to be prioritized
   • E.g. Technology platforms

2) Criteria by which alternatives are to be prioritized/ranked
   • Quantitative (future cash flow) or qualitative (platform substitutability)

3) Relative importance of the criteria
   • By using weights or points system

→ Make decision subject to budget constraint
Not one glove fits all

“Man is man because he is free to operate within the framework of his destiny. He is free to deliberate, to make decision, and to choose between alternatives”

• Martin Luther King

“Making good decisions is a crucial skill at every level”

• Peter F Drucker